In PDAC, TP53 mutations predominantly manifest as point mutations, particularly within the DNA‐binding domain, leading to the functional inactivation of p53 and subsequent loss of its tumor‐suppressive capabilities [9, 10]. This evidence concerns the gene TP53 and neoplasm.